common.study.topics.clinical

Experimental Treatment for Psoriasis

common.study.values.description

A Safety Study of LY3462817 in Participants With Psoriasis

This study is being conducted to determine how safe and how well tolerated LY3462817 is when given to participants with psoriasis. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. The study will last up to one year and one month for each participant.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - LY3462817 - IV

Administered IV

Drug - LY3462817 - SC

Administered SC

Drug - Placebo - IV

Administered IV

Drug - Placebo - SC

Administered SC

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 in Patients With Psoriasis

common.study.values.clinical-trial-id

NCT04152382

participant.views.study.view.id

azpZ8d